AFYX-007 is under clinical development by AFYX Therapeutics and currently in Phase I for Head And Neck Cancer. According to GlobalData, Phase I drugs for Head And Neck Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AFYX-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFYX-007 overview
AFYX-007 is under development for the treatment of head and neck cancer. The drug candidates are administered through oromucosal patch and developed based on Rivelin patch technology.
AFYX Therapeutics overview
AFYX Therapeutics is a biopharmaceutical company engaged in research and development of pharmaceuticals aiming for better treatment of diseases including cancer, women’s health and high-scale pain. The company is headquartered in Horsholm, Denmark.
For a complete picture of AFYX-007’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.